Eudaimonia Partners’s Vertex Pharmaceuticals VRTX Stock Holding History

Eudaimonia Partners’s Portfolio VRTX Stock Details VRTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q1	–	Sell	-4,336	Closed	-$1.25M	–	383
2022 Q4	$1.25M	Buy	4,336 +1,871	+76%	+$570K	0.31%	89
2022 Q3	$714K	Buy	+2,465	New	+$709K	0.19%	123
2021 Q2	–	Sell	-298	Closed	-$64K	–	1346
2021 Q1	$64K	Sell	298 -12	-4%	-$2.64K	0.01%	576
2020 Q4	$73K	Sell	310 -22	-7%	-$5.05K	0.02%	521
2020 Q3	$90K	Buy	332 +61	+23%	+$16.8K	0.02%	436
2020 Q2	$79K	Sell	271 -83	-23%	-$22.5K	0.03%	412
2020 Q1	$84K	Buy	354 +40	+13%	+$9.18K	0.04%	361
2019 Q4	$69K	Buy	+314	New	+$63.5K	0.03%	424

Other funds holding VRTX

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Eudaimonia Partners's VRTX Position: Q1 2023 in Review

Eudaimonia Partners sold out of Vertex Pharmaceuticals (VRTX) in Q1 2023, closing a stake of 4,336 shares — an estimated $1.25M sold.

Eudaimonia Partners first reported a position in VRTX in Q4 2019 and held it in 8 quarters. The position peaked at $1.25M in Q4 2022. 1,207 funds tracked by Wall St. Rank hold VRTX as of Q1 2023.

Eudaimonia Partners reported no remaining Vertex Pharmaceuticals position as of Q1 2023 after selling out during the quarter.
Eudaimonia Partners sold 4,336 Vertex Pharmaceuticals shares in Q1 2023, an estimated $1.25M.
Eudaimonia Partners first reported a position in Vertex Pharmaceuticals in Q4 2019 and held it in 8 quarters.
Eudaimonia Partners's Vertex Pharmaceuticals position peaked at $1.25M in Q4 2022.
1,207 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q1 2023.

Based on Eudaimonia Partners's 13F filing for Q1 2023, filed 25 Apr 2023.